Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Official title

A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer

Overview

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Interventions

• Drug Xaluritamig
  Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Primary outcome measures

• Number of Participants with Treatment-emergent Adverse Events [Time frame: Up to 3.6 Year]

Secondary outcome measures (12)

• Maximum Plasma Concentration (Cmax) of Xaluritamig [Time frame: Up to 1 Year]
• Time to Cmax (tmax) of Xaluritamig [Time frame: Up to 1 Year]
• Accumulation Ratio (AR) Following Multiple Doses of Xaluritamig [Time frame: Up to 1 Year]
• Serum Concentration Before Dosing (Ctrough) of Xaluritamig [Time frame: Up to 1 Year]
• Area Under the Concentration-time Curve Over the Dosing Interval (AUC) of Xaluritamig [Time frame: Up to 1 Year]
• Objective Response (OR) per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Time frame: Up to 3.6 Years]
• Duration of Response (DOR) per Modified RECIST v1.1 [Time frame: Up to 3.6 Years]
• Disease Control (DC) per Modified RECIST v1.1 [Time frame: Up to 3.6 Years]
• Time to Response (TTR) per Modified RECIST v1.1 [Time frame: Up to 3.6 Years]
• Number of Participants with a Prostate-specific Antigen (PSA) 50 Response [Time frame: Up to 3.6 Years]
• Number of Participants with a PSA 90 Response [Time frame: Up to 3.6 Years]
• Time to PSA 50 and PSA 90 Response [Time frame: Up to 3.6 Years]

Eligibility criteria

Inclusion criteria

• Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenocarcinoma with neuroendocrine component) are not permitted.
• mCRPC with ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scintigraphy imaging obtained within 28 days prior to enrollment.
• Evidence of progressive disease, defined as 1 or more PCWG3 criteria:

• Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
• Soft tissue progression defined as an increase ≥ 20% and an absolute increase of ≥ 5 mm in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-target lesions.
• Progression of bone disease defined by the appearance of at least 2 new bone lesions(s) by bone scintigraphy (as per the 2+2 PCWG3 criteria).
• Prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L).
• Prior progression on at least one androgen receptor pathway inhibitor (androgen receptor pathway inhibitor \[ARPI\], enzalutamide, abiraterone, apalutamide, darolutamide).
• Prior treatment with only one taxane therapy in the mCRPC setting. Prior treatment with docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is permitted; however, participants must have also received one, and only one, taxane therapy in the mCRPC setting.

Exclusion criteria

• History of central nervous system metastasis. Note: Participants with treated, asymptomatic, and clinically stable dural metastases are eligible.
• History of allergic reactions or acute hypersensitivity reactions to the components of the trial therapies and their analogs. Participants with known contraindications to high-dose corticosteroids are also excluded.
• History of malignancy that is expected to alter life expectancy or may interfere with disease assessments. Participants with prior history of malignancy that have been adequately treated and who have been disease-free for >3 years are eligible, as are participants with adequately treated non-melanoma skin cancer or superficial bladder cancer.
• Active autoimmune disease that has required systemic treatment (except physiologic replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on trial.
• Known positive test for human immunodeficiency virus.
• Presence or history of viral hepatitis infection.
• Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of trial treatment with the following exceptions:

• Androgen-deprivation therapy with luteinizing hormone-releasing hormone/gonadotropin-releasing hormone (LHRH/GnRH) analogue (agonist/antagonist) is allowed.
• ARPIs (enzalutamide, abiraterone, apalutamide, darolutamide) require a minimum washout of 2 weeks prior to the first dose of xaluritamig.
• Prior prostate-specific membrane antigen (PSMA) radionuclide therapy cannot be given within 3 months prior to first dose of xaluritamig unless participant received <2 cycles of therapy, in which case participant cannot have received PSMA radionuclide therapy within 35 days prior to first dose.
• Any prior six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted therapy.
• Any prior cluster of differentiation 3 (CD3)-directed therapy.
• Requirement for chronic systemic corticosteroid therapy (prednisone dose >10 mg/day or equivalent) or any other immunosuppressive therapies (including anti TNFα therapies).
• Participation on any other xaluritamig trial, regardless of whether xaluritamig was administered.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 9 centers

• Rocky Mountain Cancer Centers — Denver
• United States Oncology Regulatory Affairs Corporate Office — Denver
• US Oncology Research Investigational Products Center — Denver
• Thomas Jefferson University — Philadelphia
• University of Pittsburgh Medical Center Hillman Cancer Center — Pittsburgh
• Sanford Oncology Clinic and Pharmacy — Sioux Falls
• Sarah Cannon Research Institute Oncology Partners — Nashville
• University of Texas MD Anderson Cancer Center — Houston
• … and 1 more center

Australia · 2 centers

• Chris OBrien Lifehouse — Camperdown
• Monash Medical Centre — Clayton

Identifiers

NCT: NCT07493512 · 20250211

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗